127061-08-9

Basic information

• Product Name: 2,3,4-TRI-O-BENZYL-L-FUCOPYRANOSYL FLUORIDE
• Synonyms: 2,3,4-TRI-O-BENZYL-L-FUCOPYRANOSYL FLUORIDE
• CAS NO: 127061-08-9
• Molecular Formula: C₂₇H₂₉FO₄
• Molecular Weight: 436.52
• Mol File: 127061-08-9.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 533.8±50.0 °C(Predicted)
• Appearance: /
• Density: 1.18±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 2,3,4-TRI-O-BENZYL-L-FUCOPYRANOSYL FLUORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4-TRI-O-BENZYL-L-FUCOPYRANOSYL FLUORIDE(127061-08-9)
• EPA Substance Registry System: 2,3,4-TRI-O-BENZYL-L-FUCOPYRANOSYL FLUORIDE(127061-08-9)

Safety Data

• Hazardous Substances Data: 127061-08-9(Hazardous Substances Data)

Usage

General Description

2,3,4-TRI-O-BENZYL-L-FUCOPYRANOSYL FLUORIDE is a chemical compound that is often used in the synthesis of complex carbohydrates and glycoconjugates. It is a derivative of L-fucose, a common monosaccharide found in various biological molecules. The addition of benzyl groups to the fucose molecule provides protection to the hydroxyl groups, allowing for selective manipulation of the molecule during chemical reactions. The addition of a fluoride group also serves to activate the anomeric carbon, making it a useful building block for the synthesis of more complex carbohydrates. 2,3,4-TRI-O-BENZYL-L-FUCOPYRANOSYL FLUORIDE is important in the field of glycochemistry and glycobiology, as it allows for the creation of diverse carbohydrate structures for use in various applications, such as drug development and biochemical research.

Upstream product

• 169532-17-6 ethyl 2,3,4-tri-O-benzyl-1-thio-α/β-L-fucopyranoside 
• 162118-38-9 (3S,4R,5R,6S)-3,4,5-tris(benzyloxy)-6-methyltetrahydro-2H-pyran-2-ol 

Downstream Products

• 165816-42-2 C₅₈H₈₆O₁₄Si₂ 
• 190587-45-2 N-(tert-butoxycarbonyl)-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-D-seryl-D-glutamic acid 1-methylamide 5-benzyl ester 
• 190587-44-1 -L-glutamic acid 1-methylamide 5-benzyl ester 
• 190587-43-0 N-(tert-butoxycarbonyl)-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-L-seryl-D-glutamic acid 1-methylamide 5-benzyl ester 
• 190587-42-9 N-(tert-butoxycarbonyl)-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-L-seryl-L-glutamic acid 1-methylamide 5-benzyl ester 
• 294623-65-7 4-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-(2S,3R,4R)-1-benzyloxycarbonyl-3,4-dihydroxy-2-ethylpyrrolidine 
• 162128-74-7 (3aS,4R,6S,7R,7aS)-6-((2R,3S,4R)-4-Benzyloxy-2-benzyloxymethyl-3,4-dihydro-2H-pyran-3-yloxy)-4-triisopropylsilanyloxymethyl-7-((2S,3S,4R,5R,6S)-3,4,5-tris-benzyloxy-6-methyl-tetrahydro-pyran-2-yloxy)-tetrahydro-[1,3]dioxolo[4,5-c]pyran-2-one 
• 1361481-69-7 phenyl (2-O-acetyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1->4)-[2,3,4-tri-O-benzyl-α-L-fucopyranosyl-(1->3)]-6-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside 
• 1245797-75-4 N-benzyloxycarbonyl-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-L-threonine tert-butyl ester 
• 126949-19-7 C₆₅H₇₀Cl₂FNO₁₉ 
• 136543-98-1 N-[(2S,3R,4R,5S,6R)-2-Benzyloxy-6-benzyloxymethyl-5-((2S,3R,4S,5R,6R)-6-benzyloxymethyl-3,4,5-trihydroxy-tetrahydro-pyran-2-yloxy)-4-((2S,3S,4R,5R,6S)-3,4,5-tris-benzyloxy-6-methyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-3-yl]-acetamide 
• 142800-31-5 <(6-deoxy-2,3,4-tri-O-benzyl-α-L-galactopyranosyl)-(1->3)>-<(2,3,4-tri-O-benzoyl-6-O-benzyl-β-D-galactopyranosyl)-(1->4)>-1,5-anhydro-6-O-(tert-butyldiphenylsilyl)-2-deoxy-D-arabino-hex-1-enopyranose 
• 142800-33-7 <(6-deoxy-2,3,4-tri-O-benzyl-α-L-galactopyranosyl)-(1->3)>-<(6-O-benzyl-β-D-galactopyranosyl)-(1->4)>-1,5-anhydro-6-O-(tert-butyldiphenylsilyl)-2-deoxy-D-arabino-hex-1-enopyranose 
• 152932-94-0 C₆₇H₇₁NO₂₂S 

Relevant articles and documents

Total synthesis of a sialyl Lewisx derivative for the diagnosis of cancer

The total synthesis of aminoethyl glycoside of sialyl Lewisx (sLex) is described. A galactose donor was condensed with a diol of glucosamine to afford regioselectively a β1,4 linked disaccharide, which was further stereoselectively fucosylated to provide a protected Lewis x trisaccharide. After chemical modification, the trisaccharide was sialylated to give regio- and stereoselectively an azidoethyl glycoside of sLex. Finally, deprotection and azide reduction afforded the target compound. This compound will be coupled with protein and then be used to conduct further preclinical studies for the diagnosis of cancer.